# Target Identification Assessment

Identify and validate drug targets using disease-gene association data, genetic evidence, and structural druggability analysis. Prioritize targets with strong genetic evidence (GWAS, Mendelian disease, loss-of-function intolerance), available structural information (crystal structure or confident AlphaFold2 prediction), and a tractable binding site (defined pocket with appropriate properties for small-molecule binding).

## Inputs

- `disease-indication`: Target disease or phenotype to address
- `omics-data`: Available transcriptomic, proteomic, or genetic data linking genes to the disease

## Outputs

- `target-shortlist`: Ranked targets with genetic evidence score, druggability assessment, and structural availability
- `target-profiles`: Per-target profile: gene, protein function, expression pattern, existing drugs/tools, binding site analysis

## Process

1. Mine genetic evidence: query Open Targets Platform for disease-gene associations aggregating GWAS (genome-wide significant loci with eQTL colocalization), rare disease (ClinVar pathogenic variants, OMIM), somatic mutations (COSMIC driver genes), and animal model phenotypes. Targets with multiple independent lines of genetic evidence have higher clinical success probability.
2. Assess loss-of-function tolerance from gnomAD constraint metrics: pLI (probability of loss-of-function intolerance) > 0.9 indicates the gene is essential and modulation may have safety concerns. LOEUF (loss-of-function observed/expected upper fraction) < 0.35 indicates strong intolerance. This informs whether inhibition vs activation is safer.
3. Evaluate tissue expression: target should be expressed in disease-relevant tissue (GTEx, Human Protein Atlas). Broad essential expression increases on-target toxicity risk. Ideal targets have enriched expression in disease tissue relative to safety-critical organs (heart, liver, brain).
4. Structural druggability assessment: obtain structure (PDB experimental or AlphaFold2 prediction with pLDDT > 70 in binding region). Run fpocket or SiteMap to identify and score binding pockets. Druggable pockets: volume 200-1000 cubic Angstrom, hydrophobicity score > 0.5, enclosure > 0.5. Allosteric sites may be identified from MD simulations (cryptic pockets that open during dynamics).
5. Check existing chemical matter: search ChEMBL for known bioactive compounds against the target (IC50/Ki < 10 micromolar). Existing tool compounds de-risk the target and provide starting points for lead optimization. If no chemical matter exists, assess tractability from structural features and protein family druggability statistics.
6. Compile competitive landscape: identify drugs in clinical trials targeting the same protein (ClinicalTrials.gov) or pathway. First-in-class targets carry higher risk but also higher reward. Fast-follower programs must differentiate on selectivity, safety, or pharmacokinetics.

---

Copyright 2024-present The Wayfinder Trust. All rights reserved.
